PPL
Therapeutics, the company that helped to create Dolly, the world’s first cloned
sheep, is to shed up to 90 per cent of its staff.
The
biotechnology firm announced the move after a project to develop treatment for
lung disorders was dropped by its German partners.
Bayer,
the German drugs giant, put the programme to commercialise the new medicine AAT
– made from the milk of genetically modified sheep – on hold for at least three
years.
Sign up to our weekly round-up of HR news and guidance
Receive the Personnel Today Direct e-newsletter every Wednesday
Edinburgh-based
PPL will lay off between 90 and 140 staff. Chief executive Geoff Cook said the
decision had no reflection on "the significant endeavours of our
workforce".
